Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 747

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 747
---
 (ii) the commencement of a clinical study intended to be used as a definitive study for market approval in any country, the Company is 
 obligated to pay an aggregate amount of $300 in cash or an equivalent amount of common stock, with $240 to St. Cloud and $60 to an employee of the Company; and                                                                              |

F-16

| • |     | Upon receipt of regulatory approval of REM-001 Therapy, the Company is                                                                                       
 obligated to pay an aggregate amount of $700 in cash or an equivalent amount of common stock, with $560 to St. Cloud and $140 to an employee of the Company. |

With respect to the $300 and $700 potential milestone payments referenced above (each a “Milestone Payment”), if either such Milestone Payment becomes payable, and in the event the Company elects to pay either such Milestone Payment in shares of its common stock, the value of the common stock will equal the average of the closing price per share of the Company’s common stock over the twenty (20) trading days following the first public announcement of the applicable event described above. The milestone payment liability has been estimated using a scenario-based method (or “SBM”). An SBM is an income-based approach under which possible outcomes are identified, the contingent consideration payoff of each outcome is probability weighted, and then a suitable discount rate is used to arrive at the expected present value of the contingent consideration at the valuation date. The probability used in the valuation was based on published research for the probability of success of oncology companies at a similar stage of development as the Company. The discount rate was based on published rates for corporate bonds and the term was based on an estimate of the planned timing of completion of the respective development achievement that would result in payment of the respective milestones.

| Balance – June 30, 2022       |     | $              
 (in thousands) | 163 |
|:------------------------------|:----|:---------------|----:|
| Change in fair value estimate |     |                |   3 |
| Balance – June 30, 2023       |     |                | 166 |
| Change in fair value estimate |     |                |  20 |
| Balance – June 30, 2024       |     |                | 186 |

8. Stockholders’ equity Preferred stock Series C Preferred Stock

|                                                        |     | Series C Preferred Stock |        |   |     |                |        |   |
|                                                        |     | Number                   
 of shares